Inozyme Pharma Inc Ordinary Shares Azioni (NASDAQ: INZY)

Ultime notizie per Inozyme Pharma Inc Ordinary Shares (NASDAQ:INZY) Azioni

INOZYME PHARMA INC

Inozyme Pharma

<a href="https://x.com/PatentAlerts4/status/1942312161243718143" title="https://x.com/PatentAlerts4/status/1942312161243718143">https://x.com/PatentAlerts4/status/1942312161243718143</a>

Biotech

General

NDRA

ENDRA Life Sciences To Be Granted US Patent 'Radio Frequency Applicator.'

NBTX

NANOBIOTIX Announces Announces European Health Authorities Agreed To Formally Reclassify NBTXR3 From A Medical Device To A Drug

Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares are trading lower Monday afternoon as markets react to new global trade restrictions announced by the White House. President Donald Trump imposed sweeping 25% tariffs on all goods imported from Japan and South Korea, set to begin Aug. 1.
What To Know: The broad-based duties, which come after a 90-day negotiation period <a href="https://www.benzinga.com/markets/equities/25/07/46281204/wall-street-today-trump-tariffs-japan-south-korea-stocks-drop">expired</a> without a resolution, add to existing tariffs and aim to correct &#8220;unsustainable trade deficits.&#8221;
In official letters, the administration noted the 25% rate was a &#8220;moderate&#8221; measure. The news sent a chill through markets, impacting multinational corporations like Intel that rely on complex global supply chains.
Adding to investor concerns, the administration is <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46282961/super-micro-shares-are-trading-lower-monday-whats-going-on">reportedly preparing</a> to restrict shipments of advanced AI chips to Malaysia and Thailand to prevent the technology from reaching China. 
As a result, the potential for new export licenses and controls on high-performance semiconductors casts a shadow over the entire industry. These dual threats of broad tariffs and specific chip curbs, combined with a looming tariff deadline with the European Union, are weighing heavily on sentiment for major U.S. chipmakers.
Benzinga Edge Rankings: According to <a href="http://benzinga.grsm.io/register174">Benzinga&#8217;s Edge</a> stock rankings, Intel presents a profile that may appeal strongly to value-oriented investors. The stock earns a high value score of 74.75, suggesting it could be trading at a discount relative to its intrinsic worth or industry peers.
However, this strength is contrasted by significant weakness in other key areas. Intel scores poorly on Momentum at 26.55 and receives a very low mark for Growth at 19.18. A ranking for the stock&#8217;s Quality was not available. This data indicates that while Intel may represent a bargain.
INTC Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Intel shares closed Monday down 2.18% to $22. The stock has a 52-week high of $37.16 and a 52-week low of $17.66.
<h2 class="wp-block-heading">How To Buy INTC Stock</h2>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Intel&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Read Also: • <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46282961/super-micro-shares-are-trading-lower-monday-whats-going-on">Super Micro Shares Are Trading Lower Monday: What&#8217;s Going On?</a>
Image: Shutterstock

News

Global

Movers

Tech

INTC

Intel Shares Tumble On Sweeping Tariffs, AI Chip Curbs

Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) has outperformed the market over the past 5 years by 44.98% on an annualized basis producing an average annual return of 59.32%. Currently, Vistra has a market capitalization of $65.73 billion. 
Buying $100 In VST: If an investor had bought $100 of VST stock 5 years ago, it would be worth $1,019.47 today based on a price of $193.70 for VST at the time of writing.
<h3>Vistra's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751919311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Vistra 5 Years Ago Would Be Worth This Much Today

Benchmark analyst David Williams maintains IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy and raises the price target from $50 to $55.

Price Target

Analyst Ratings

IONQ

Benchmark Maintains Buy on IonQ, Raises Price Target to $55

Guidance

MMSI

Merit Medical Sees Prelim. Q2 Revenue $380M-$384M

PBBK

Trading Halt: Halted at 4:10:00 p.m. ET - Trading Halt: Halt News Pending

LAMR

Lamar Advertising Acquires Verde Outdoor's Assets In UPREIT Transaction; Terms Not Disclosed

CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) just made a big move — but the market didn't applaud. Shares of Core Scientific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) plunged nearly 21% on Monday, even as AI cloud provider CoreWeave announced it will acquire the Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) miner in <a href="https://www.benzinga.com/topic/bitcoin-miners">an all-stock deal</a>.
The twist? 
Beth Kindig, CEO and Lead Tech Analyst at I/O Fund, flagged the valuation in a post on X:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">CoreWeave <a href="https://twitter.com/search?q=%24CRWV&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CRWV</a> has agreed to acquire Core Scientific <a href="https://twitter.com/search?q=%24CORZ&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CORZ</a> in an all-stock transaction expected to close in Q4. The exchange ratio implies a $9 billion equity valuation for <a href="https://twitter.com/search?q=%24CORZ&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CORZ</a>, or $20.40 per share value.
&mdash; Beth Kindig (@Beth_Kindig) <a href="https://twitter.com/Beth_Kindig/status/1942202259799957952?ref_src=twsrc%5Etfw">July 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The exchange ratio values Core Scientific at a jaw-dropping $9 billion — or $20.40 per share, a massive premium over its pre-deal price of under $11. That's a valuation level this Bitcoin mining company could have secured only during the heady crypto boom days of 2021. And markets aren't buying it.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46280108/coreweave-core-scientific-shares-move-lower-on-9-billion-all-stock-deal">CoreWeave, Core Scientific Shares Move Lower On $9 Billion All-Stock Deal</a>
CoreWeave's stock also dipped 3.9% on the news, despite its own red-hot 293% year-to-date rally. While the company touts the acquisition as a strategic play to vertically integrate and secure cheap, scalable power for its AI infrastructure, investors seem skeptical of marrying high-growth AI with high-volatility crypto mining.
That's a head-turner in today's market, where Bitcoin miners have struggled with compressed margins, regulatory uncertainty, and post-halving revenue pressure. 
Core Scientific is down 12% in the past month and still negative year-to-date — yet CoreWeave's offer implies nearly double the current share price.
CoreWeave's bullish bet hinges on AI's insatiable energy appetite. Owning a Bitcoin mining company such as Core Scientific, which operates massive power-dense data centers, could give CoreWeave better control over energy infrastructure. But the question remains: Can a 2021-style crypto valuation fly in a 2025 market?
For now, the answer from investors is a resounding, "not yet."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46273662/no-plan-b-teslas-musk-premium-is-on-thin-ice">No Plan B &#8211; Tesla&#8217;s Musk Premium Is On Thin Ice</a></li>
</ul>
Photo: PJ McDonnell via Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

Markets

$BTC

Core Scientific, Inc. - Class A Common Stock

CORZ

CRWV

CoreWeave Just Valued Core Scientific Like It's 2021 Again

Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors
Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025

Management

Merit Medical Names Martha Aronson As President And CEO

Contracts

OPXS

Optex Systems Receives $2.8M Purchase Order For Optical Sighting System

Cadence Design Systems, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) shares are lower Monday. They have found resistance around $325 again.
But they may be on the <a href="https://www.benzinga.com/news/25/07/46256825/nvidia-crowdstrike-wolfspeed-cadence-design-systems-and-microsoft-why-these-5-stocks-are-on-investors-radars-today">verge of a breakout</a>. This is why our technical analysis team has made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
In the stock market, certain price levels have more importance than others. As you can see on the chart below, the $325 level is one for Cadence.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="531" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one-1024x531.png" alt="" class="wp-image-975421" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one-1024x531.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one.png 1402w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
In early 2024, the stock was trending higher. There weren't enough sell orders to fill all of the buy orders. Those who wished to buy had to continually increase their bid prices to attract sellers into the market. This forced the shares into an uptrend.
In March 2024, the uptrend ended around $325.
There were enough sell orders to fill all of the buy orders. The buyers didn't need to keep pushing the price higher.
But soon after hitting this resistance, the shares reversed and headed lower. When this happened, some people thought their decision to buy was a mistake.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/07/46271577/trumps-big-beautiful-bill-slashes-solar-incentives-cathie-woods-ark-says-nuclear-may-now-be-cheapest-option-oklo-smr-ltbr-and-other-stocks-in-focus">Trump&#8217;s Big Beautiful Bill Slashes Solar Incentives — Cathie Wood&#8217;s Ark Says Nuclear May Now Be Cheapest Option: OKLO, SMR, LTBR And Other Stocks In Focus</a>
They also decided to get out at breakeven if they could eventually do so.
So when Cadence returned to this level in June 2024, these regretful buyers placed sell orders. And there were so many of them that it created resistance again at the same level.
A similar dynamic occurred in December. Remorseful buyers who paid around $325 in June 2024 saw a chance to finally get out at breakeven, and they took it. Their selling put a top on the price once again.
Then, some of the people who had bought shares attempted to exit at breakeven after the price returned to this level in January.  And again, resistance formed.
Now Cadence has returned to this important level once more. The same thing could happen.
However, if the stock can break out above $325, it will indicate that the sellers are no longer present. They have either canceled or finished their orders.
With these sellers out of the way and this large amount of supply taken off of the market, those who wish to buy may start to push the price higher again.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46276421/broadcom-tesla-mag-7-switch-musk-trump-feud">Musk Chaos Could Oust Tesla From Mag 7, Making Way For Broadcom</a></li>
</ul>
Image: Shutterstock

Technicals

CDNS

Stock Of The Day: Breakout Time For Cadence Design?

Horizon, a company offering tailored investment and technology solutions to financial advisors, is introducing two new actively managed ETFs: Horizon Core Bond ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BNDY#BATS">BNDY</a>) and Horizon Flexible Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#BATS">FLXN</a>). This expansion continues the company&#8217;s growth in its fast-growing <a href="https://www.benzinga.com/etfs">ETF family.</a>
Both are structured to assist advisors in producing a steady income while managing risk using options overlays, a strategy that is growing in popularity due to interest rate uncertainty and volatile credit markets.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46277766/tesla-troubles-amplified-by-musks-party-politics-etfs-on-edge">Tesla Troubles Amplified By Musk&#8217;s Party Politics: ETFs On Edge</a>
BNDY focuses on investment-grade fixed-income instruments across a range of maturities like government and corporate bonds, and adds put spread overlays to enhance return potential and buffer volatility. The fund carries an expense ratio of 0.65%.
FLXN, on the other hand, ventures into the high-yield debt space, providing flexibility to adjust holdings based on market conditions, once more employing put spread overlays to cushion downside risk and maximize returns. The expense ratio for this fund is 0.80%.
The launch follows hot on the heels of three other ETF rollouts by Horizon just last week, Horizon Core Equity ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/STOX#BATS">STOX</a>), Horizon Dividend Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/DIVN#BATS">DIVN</a>), and Horizon Managed Risk ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/SFTY#BATS">SFTY</a>), bringing the firm&#8217;s ETF lineup to seven.
As fixed-income investing evolves, Horizon&#8217;s latest ETFs represent another step in providing advisers with more nimble and risk-conscious solutions in an increasingly complex market environment.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46281860/elons-america-party-etf-a-what-if-fund-of-musk-linked-stocks-like-tesla-nvidia">Elon&#8217;s America Party ETF: A What-If Fund Of Musk-Linked Stocks Like Tesla, Nvidia</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

BNDY

DIVN

FLXN

SFTY

STOX

Horizon Expands ETF Lineup With 2 Funds For Smarter Bond Income And Volatility Defense

Earnings

EDUC

Educational Development Q1 EPS $(0.13) Up From $(0.15) YoY, Sales $7.100M Down From $9.993M YoY

Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held July 12-15, 2025, in San Francisco. Dr. Aliya Khan will present new data from Week 156 of the Company's Phase 3 PaTHway Trial demonstrating the safety and efficacy of long-term treatment with TransCon&#xAE; PTH (palopegteriparatide) in adults with hypoparathyroidism – including maintenance of serum and urine biochemistries within normal levels and sustained improvement in renal function. Dr. Carlos Bacino will present additional safety and tolerability data from Week 52 of the Company's pivotal ApproaCH Trial of once-weekly TransCon&#xAE; CNP (navepegritide) in children with achondroplasia.

ASND

Ascendis Pharma To Present New Data From Week 156 Of Phase 3 PaTHway Trial Demonstrating Safety And Efficacy Of Long-Term Treatment With TransCon PTH In Adults With Hypoparathyroidism, At ENDO 2025

Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) shares are trading lower on Monday amid possible trade tensions. It was reported that the U.S. is planning to restrict shipments of AI chips to Malaysia and Thailand over China concerns.
According to the&nbsp;<a href="https://www.latimes.com/business/story/2025-07-05/u-s-plans-ai-chip-curbs-on-malaysia-thailand-over-china-concerns?utm_source=chatgpt.com">Los Angeles Times</a>, President Donald Trump's administration is planning new export restrictions that would require U.S. companies to obtain licenses before sending advanced AI chips to Malaysia and Thailand. The goal is to prevent the indirect transfer of sensitive technology to China.
The updated rules, expected to be proposed as soon as August, target countries that have recently seen a rise in chip-related investment and activity.
The measures will likely include temporary exemptions, allowing shipments from U.S. and allied companies to continue for a limited time without a license. Additional exceptions are also being considered to reduce potential supply chain disruptions.
Officials are also expected to scale back a separate rule on AI chip exports that had faced pushback from U.S. allies and tech firms like Nvidia.
Current restrictions on exports to China and over 40 other countries will stay in effect to curb smuggling and closely monitor sensitive markets.
QCOM Price Action: At publication on Monday, Qualcomm shares are trading 2.54% lower at $158.09, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwiWjf6OuKuOAxXbAHkGHVuJE9IQFnoECA4QAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Read Now: • <a href="https://www.benzinga.com/news/politics/25/07/46283137/trump-vs-bezos-how-big-beautiful-bill-may-wreck-20k-ev-dream">Trump Vs. Bezos: How &#8216;Big Beautiful Bill&#8217; May Wreck $20K EV Dream</a>
Image via Shutterstock

QCOM

Qualcomm Stock Is Trading Lower Monday: What's Going On?

<a href="https://register.epo.org/application?number=EP20832031">https://register.epo.org/application?number=EP20832031</a>

MBRX

Moleculin Biotech Has Been Granted European Patent Number EP3990041 titled "METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN (FOR THE TREATMENT OF CANCER)

BFST

Business First Bancshares To Acquire Progressive Bancorp, Inc. And Progressive Bank; Expects To Issue ~3,050,490 Shares Of Common Stock To Progressive Shareholders

Ratings for Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.0, a high estimate of $42.00, and a low estimate of $22.00. This current average has increased by 7.41% from the previous average price target of $27.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1751918503_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Allegro Microsystems's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Allegro Microsystems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Allegro Microsystems compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Allegro Microsystems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Allegro Microsystems's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALGM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Allegro Microsystems analyst ratings.</a>
<h2>Discovering Allegro Microsystems: A Closer Look</h2>
Allegro Microsystems Inc is a designer, developer, fabless manufacturer, and marketer of sensor ICs and application-specific analog power ICs for automotive and industrial markets. Its Sensor IC allows customers to precisely measure motion, speed, position, and current, and Power ICs include high-temperature and high-voltage capable motor drivers, power management, and LED driver ICs. Its products are divided into three categories such as SENSE which includes Current Sensors, Switches and Latches, and Interface ICs among others; REGULATE which includes Regulators, ClearPower Modules, and LED Drivers; and DRIVE which includes BLDC Drivers, Brush DC, and others. Key revenue for the company is generated from Greater China and the rest from the United States, Japan, Europe, and other regions.
<h3>A Deep Dive into Allegro Microsystems's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Allegro Microsystems's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -19.85%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Allegro Microsystems's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -7.68%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Allegro Microsystems's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.59%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Allegro Microsystems's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.03%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Allegro Microsystems's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.4, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGM

Breaking Down Allegro Microsystems: 10 Analysts Share Their Views

In the last three months, 13 analysts have published ratings on Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $176.38, a high estimate of $225.00, and a low estimate of $140.00. This current average represents a 11.03% decrease from the previous average price target of $198.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1751918487_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Qualcomm by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Tal Liani</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$157.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$155.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$140.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$190.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$216.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Joshua Buchalter</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$160.00</td>
<td>$195.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Qualcomm. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Qualcomm compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Qualcomm's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Qualcomm's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/QCOM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Qualcomm analyst ratings.</a>
<h2>Get to Know Qualcomm Better</h2>
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.
<h3>Financial Insights: Qualcomm</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Qualcomm's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.93% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Qualcomm's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 25.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Qualcomm's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 10.3%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.07%, the company showcases effective utilization of assets.
Debt Management: Qualcomm's debt-to-equity ratio stands notably higher than the industry average, reaching 0.53. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Qualcomm's Future

Press Releases

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZY

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TXNM, SVT, INZY, PTIX on Behalf of Shareholders

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVDX, TASK, INZY on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders

Small Cap

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, SVT, HLGN on Behalf of Shareholders

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

Comments

Inozyme Pharma Inc Ordinary Shares

Notizie

Ultime notizie per Inozyme Pharma Inc Ordinary Shares (NASDAQ:INZY) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO